IDH1 and glioma: Encouraging by promising inhibitory activities of clomifene on mutant IDH1 enzymes activity, in consideration of both IDH1R132H and IDH1R132C concomitant gain of the same neomorphic function that reduce α-KG to D-2-hydroxyglutaricacid (D-2HG) using NADPH as the cofactor, human fibrosarcoma cell line HT1080 harboring R132C mutation of IDH1, the most common IDH mutation in glioma, was selected to further examined for its biological activity in vitro [15].